Ann: Appendix 4C - quarterly, page-5

  1. 384 Posts.
    lightbulb Created with Sketch. 5
    I'll second that A :

    And there are a number of potentials:
    Othepedics
    Intravenous
    MSC (Crohns/GVHD)
    Japan (excluding JCR)

    According to MSB website , we currently have 2 partnered (Teva ;JCR)

    The comment by Jason below re a potential  3rd partnering for  a P2 application is interesting as I always envisaged the 3rd deal to be P3 Orthopedics (spinal fusion).

    If anyone has access to Jason's note - it would be interesting to understand what P2 application he is referring to ?

    Good luck all.

    Jason Zhang, Edison Investment Research (5/27/14) "Mesoblast Ltd. intends to initiate a Phase 3 trial of mesenchymal precursor cells in discogenic low back pain later this year, following the successful Phase 2 trial that reported in February. . .now a leading contender in the field, Mesoblast could have five active programs in Phase 3 (two partnered) and four in Phase 2 studies (one partnered) with nine clinical candidates by the end of this year. We expect CEP-41750 to become the leading stem cell therapy for congestive heart failure."
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.63
Change
0.015(0.93%)
Mkt cap ! $2.082B
Open High Low Value Volume
$1.63 $1.67 $1.61 $6.975M 4.265M

Buyers (Bids)

No. Vol. Price($)
1 707 $1.63
 

Sellers (Offers)

Price($) Vol. No.
$1.64 7320 2
View Market Depth
Last trade - 16.10pm 04/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.